Research is split on whether semaglutide causes problematic muscle loss — some studies show the lean-to-fat ratio improves, while larger trials show significant lean mass reduction.
Lean-to-total ratio may improveDespite absolute lean mass decreasing, some studies found the proportion of body mass that's muscle actually increases because fat is lost faster — complicating the narrative
What the researchers found
The evidence on semaglutide's impact on lean mass (muscle) is contradictory. Some studies show that while semaglutide causes decreases in both lean mass and fat mass, the ratio of lean mass to total body mass actually improves — meaning fat is lost proportionally faster than muscle. However, larger clinical trials have found significant reductions in lean mass, raising concerns about muscle loss.
This contradiction makes the real-world impact unclear: semaglutide users are definitely losing some muscle along with fat, but whether this represents a clinically meaningful problem — or simply the normal lean mass loss that accompanies any significant weight reduction — remains debated.
Why it matters
With millions of people now taking semaglutide for weight loss, the question of whether they're losing dangerous amounts of muscle is urgent. Muscle loss can lead to weakness, falls (especially in older adults), metabolic slowdown, and the characteristic "Ozempic face" and "Ozempic butt" that have drawn media attention. Understanding the true impact on lean mass is essential for guiding exercise recommendations, protein intake, and patient selection for GLP-1 therapy.
The numbers in context
Opinion paper synthesizing conflicting evidence · Lean-to-total body mass ratio may improve · Larger trials show significant lean mass reduction · No specific effect sizes reported
How the study worked
This is an opinion paper published in Clinical Nutrition that synthesizes and interprets existing research on semaglutide's effects on body composition, specifically lean mass. It discusses findings from multiple investigations and clinical trials to frame the current state of the debate.
Who was studied
Discussion of research in overweight/obese and type 2 diabetes patients treated with semaglutide
What this study cannot tell us
As an opinion paper rather than a systematic review or meta-analysis, the evidence synthesis is selective rather than comprehensive. No specific effect sizes, percentages of lean mass loss, or trial-level data are reported in the abstract. The paper identifies the controversy but doesn't resolve it.
How to read the evidence
This is a preliminary-grade opinion paper that highlights conflicting evidence rather than providing definitive conclusions. While it synthesizes relevant research, it lacks systematic methodology and doesn't resolve the controversy.
When this study was published
Published in 2025, this is a very current paper reflecting the urgent debate around body composition changes in the millions of people now using GLP-1 drugs for weight loss.
The bigger picture
The lean mass question has become one of the most important unresolved issues in GLP-1 medicine. It directly affects clinical guidance around exercise during treatment, protein intake recommendations, and whether resistance training should be considered essential rather than optional for GLP-1 users. It also intersects with the growing interest in combining GLP-1 drugs with myostatin inhibitors or other muscle-preserving agents to optimize body composition outcomes.
Questions still open
- Can resistance training fully prevent the lean mass loss associated with semaglutide, or is some loss inevitable?
- Is the lean mass loss from semaglutide different from that seen with equivalent weight loss from diet and exercise alone?
- Should older adults or those with sarcopenia be prescribed semaglutide differently to protect muscle mass?
Common questions
Should I be worried about losing muscle on semaglutide?
What does 'lean-to-total body mass ratio improves' actually mean?
Read the original research
Beyond fat: Does semaglutide affect lean mass?
Clinical nutrition (Edinburgh, Scotland), 44, 104-108
Citation
Jamialahmadi, Tannaz; Eid, Ali H; Gadde, Kishore M; Almahmeed, Wael; Kroh, Matthew; Al Zein, Mohammad; Sahebkar, Amirhossein. (2025). Beyond fat: Does semaglutide affect lean mass?. Clinical nutrition (Edinburgh, Scotland), 44, 104-108. https://doi.org/10.1016/j.clnu.2024.12.004